These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Etoposide, dexamethasone, and continuous-infusion cyclophosphamide with G-CSF for VAD-resistant multiple myeloma. Grau E; Real E; Torrecillas MT Am J Hematol; 1995 Jun; 49(2):170. PubMed ID: 7539582 [No Abstract] [Full Text] [Related]
4. High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. Long GD; Chao NJ; Hu WW; Negrin RS; Wong RM; Blume KG Cancer; 1996 Dec; 78(12):2502-9. PubMed ID: 8952558 [TBL] [Abstract][Full Text] [Related]
6. HyperCVAD for VAD-resistant multiple myeloma. Dimopoulos MA; Weber D; Kantarjian H; Delasalle KB; Alexanian R Am J Hematol; 1996 Jun; 52(2):77-81. PubMed ID: 8638645 [TBL] [Abstract][Full Text] [Related]
7. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
8. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C J BUON; 2007; 12(1):41-4. PubMed ID: 17436400 [TBL] [Abstract][Full Text] [Related]
9. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422 [TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Giles FJ; Wickham NR; Rapoport BL; Somlo G; Lim SW; Shan J; Lynott AM Am J Hematol; 2000 Mar; 63(3):125-30. PubMed ID: 10679801 [TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
12. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. Tarella C; Boccadoro M; Omedé P; Bondesan P; Caracciolo D; Frieri R; Bregni M; Siena S; Gianni AM; Pileri A Bone Marrow Transplant; 1993 Apr; 11(4):271-7. PubMed ID: 7683551 [TBL] [Abstract][Full Text] [Related]
13. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Fosså A; Muer M; Kasper C; Welt A; Seeber S; Nowrousian MR Leukemia; 1998 Mar; 12(3):422-6. PubMed ID: 9529138 [TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257 [TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma. Palumbo A; Boccadoro M; Bruno B; Triolo S; Pileri A Haematologica; 1994; 79(6):513-8. PubMed ID: 7534745 [TBL] [Abstract][Full Text] [Related]
16. Early myeloablative therapy for multiple myeloma. Alexanian R; Dimopoulos MA; Hester J; Delasalle K; Champlin R Blood; 1994 Dec; 84(12):4278-82. PubMed ID: 7994043 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma. Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137 [TBL] [Abstract][Full Text] [Related]
18. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306 [TBL] [Abstract][Full Text] [Related]
19. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Lazzarino M; Corso A; Barbarano L; Alessandrino EP; Cairoli R; Pinotti G; Ucci G; Uziel L; Rodeghiero F; Fava S; Ferrari D; Fiumanò M; Frigerio G; Isa L; Luraschi A; Montanara S; Morandi S; Perego D; Santagostino A; Savarè M; Vismara A; Morra E Bone Marrow Transplant; 2001 Nov; 28(9):835-9. PubMed ID: 11781643 [TBL] [Abstract][Full Text] [Related]
20. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial. Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]